Abstract
Objectives To determine if motor evoked potentials (mEP) – stimulation-induced muscle activation measured using electromyography – can serve as a biomarker of corticobulbar (CBT) and corticospinal (CST) tract activation for deep brain stimulation (DBS) programming.
Methods In 12 patients with Parkinson’s disease and subthalamic or pallidal DBS, contact mapping determined clinical motor side effect thresholds. For equivalent stimulation parameters, EMG was recorded from cranial and arm muscles to determine the presence, peak amplitudes and latencies of mEP. Clinical and mEP thresholds were compared and accuracy metrics calculated to assess similarity between mEP and reported side effects.
Results The mEP amplitudes increased with stimulation intensity. Latencies were shorter for cranial muscles, which were more likely to generate an mEP. Clinical and mEP thresholds were significantly correlated (R2 = 0.31; p=0.0006), although most mEP thresholds were lower than clinical side effect thresholds. The mEP accuracy in predicting side effects was 0.72, with a sensitivity of 0.68 and a specificity of 0.73.
Conclusions EMG-recorded mEP correlated well with clinical side effects, and mEP often indicated subclinical CBT and CST activations.
Significance This study characterizes motor potentials evoked by DBS and demonstrates their utility as an objective biomarker for motor side effect threshold detection during DBS programming.
Highlights
- Deep brain stimulation can activate corticospinal/bulbar tract and evoke motor potentials in muscles measurable by surface EMG
- Motor evoked potential thresholds correlate significantly with clinical side effect thresholds but occur at lower stimulation intensities
- Motor evoked potentials may be a useful side effect biomarker for deep brain stimulation programming
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) (R01 NS125143 and K23 NS097576).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Emory University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors after final publication.
